15837-45-3

Upstream product

• 64-10-8 phenyl carbamate 
• 105-56-6 ethyl 2-cyanoacetate 
• 15837-46-4 6-amino-N₁-phenyl-2-thiouracil 
• 62-53-3 aniline 
• 15837-43-1 N-cyanoacetyl-N'-phenyl-urea 
• 103-85-5 monophenylthiourea 
• 15837-44-2 1-Phenyl-3-cyanacetyl-thioharnstoff 

Downstream Products

• 110554-31-9 2,4-dioxo-1,7-diphenyl-1,2,3,4-tetrahydro-pyrido[2,3-d]pyrimidine-5-carboxylic acid 
• 109516-00-9 6-acetyl-5-methyl-1-phenyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 
• 124135-54-2 6-[1-(2,6-dioxo-3-phenyl-1,2,3,6-tetrahydro-pyrimidin-4-ylimino)-ethyl]-5-methyl-1-phenyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 
• 112271-76-8 2,4-dioxo-1,7-diphenyl-1,2,3,4-tetrahydro-pyrido[2,3-d]pyrimidine-5-carboxylic acid ethyl ester 
• 102233-00-1 7-methyl-2,4-dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrido[2,3-d]pyrimidine-5-carboxylic acid ethyl ester 
• 42212-19-1 6-amino-3-methyl-1-phenylpyrimidine-2,4(1H,3H)dione 
• 15018-50-5 1-phenyl-pyrimidine-2,4,6-trione 
• 90254-41-4 methyl 2-cyano-3-methylthio-3-(1,2,3,4-tetrahydro-2,4-dioxo-1-phenyl-6-pyrimidinyl)aminoacrylate 
• 90254-48-1 5-amino-6-cyano-7-methylthio-1-phenylpyrido<2,3-d>pyrimidine-2,4(1H,3H)-dione 
• 132373-26-3 1-Phenyl-5-cyanoacetyl-6-aminouracil 
• 70371-53-8 5-amino-7-methylthio-1-phenylpyrimido<4,5-d>pyrimidine-2,4(1H,3H)-dione 
• 15886-45-0 6-amino-5-nitroso-1-phenyl-1,3-dihydropyrimidine-2,4-dione 
• 15837-47-5 1-phenyl-2,4-dioxo-5,6-diaminopyrimidine 

Relevant academic research and scientific papers

Construction of Dihydropyrido[2,3- d]pyrimidine Scaffolds via Aza-Claisen Rearrangement Catalyzed by N-Heterocyclic Carbenes

N-Heterocyclic carbenes (NHCs) catalyzing aza-Claisen rearrangement of α,β-unsaturated enals with cyclic vinylogous amides under oxidative conditions generating potentially biologically active dihydropyridinone-fused uracils have been developed. This strategy represents a unique NHC-activation-based path with the use of 6-aminouracils as stable α,β-diEWG cyclic vinylogous amides for the efficient synthesis of bicyclic N-unprotected lactams similar to those in many useful drugs.

Carboxylic acid-catalyzed one-pot synthesis of cyanoacetylureas and their cyclization to 6-aminouracils in guanidine ionic liquid

A novel, one-pot, carboxylic acid-catalyzed synthesis of cyanoacetylureas via in situ generated ureas and their cyclization to 6-aminouracils in the presence of the guanidine-based ionic liquid 1,1,3,3-tetramethylguanidine lactate [TMG][Lac] is described. The ureas were synthesized from amines and potassium cyanate, which on reaction with cyanoacetic acid in the presence of acetic anhydride in the same pot afforded cyanoacetylureas, which undergo cyclization in [TMG][Lac] as solvent as well as catalyst to afford 6-aminouracils. One-pot synthesis of cyanoacetylureas, efficient and rapid cyclization, better yield, shorter reaction time, easy workup procedure, and recyclability of the ionic liquid are some advantages of this procedure.

Ionic liquid mediated one-pot synthesis of 6-aminouracils

A novel, one-pot synthesis of 6-aminouracils via in situ generated ureas and cyanoacetylureas in the presence of an ionic liquid catalyst, 1,1,3,3-tetramethylguanidine acetate, is described. The catalyst can be recycled for five consecutive runs without loss of activity. The mechanism for the ring closure of cyanoacetylurea to 6-aminouracil is also discussed.

Tricyclic Pyrimidine Derivatives as Wnt antagonists

The present invention relates to compounds having the general formula (I) with the definitions of X1 - X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

PYRIDO [2, 3-D] PYRIMIDINES AS WNT ANTAGONISTS FOR TREATMENT OF CANCER AND ARTHRITIS

Compounds according to the general formula (I) their solvates, hydrates, esters and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer

XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS

Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

A2B adenosine receptor antagonists

Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

Therapeutic agent for dermatitis

The present invention provides a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, which is very safe and which shows few adverse side-effects in comparison to, for example, steroidal agents. The present invention r

A novel ring closure reaction for the preparation of 6-aminouracils with an α-branched 1-substituent

The preparation of 6-aminouracil derivatives is described involving a novel, silicon-promoted ring closure reaction. Condensation of N-substituted urea with cyanoacetic acid yields cyanoacetylureas, which are heated in hexamethyldisilazane/trimethylchlorosilane to afford N-substituted 6- aminouracils. Previously unaccessible derivatives bearing an α-branched 1- substituent, including 6-amino-1-(1-phenylethyl)uracil were obtained.

Reactions of nitriles under acidic conditions : Part IX - Synthesis of 6-amino-1-aryluracils, 6-amino-1-aryl-2-thiouracils and 6-amino-1,3-diaryl-2-thiouracils under acidic conditions

6-Amino-1-aryluracils (11a-g), 6-amino-1-aryl-2-thiouracils (12a-g), and 6-amino-1,3-diaryl-2-thiouracils (6a,b) have been synthesised through the dry hydrogen chloride gas-catalysed condensation of ethyl cyanoacetate (7) with appropriate arylureas and thioureas. 1-Aryl (12a-g) and 1,3-diaryl-2-thiouracils (6c-g) have been converted to the corresponding 1-aryl (15a-g) and novel hitherto unre-ported, 1,3-diaryluracils (5a-e) through their oxidative desulphurisation.